Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

ABSTRACT: This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.

DISEASE(S): Rectum Cancer,Metastatic Colorectal Cancer,Rectal Neoplasms,Pancreas Cancer,Colon Cancer,Recurrent Colorectal Carcinoma,Colorectal Neoplasms,Pancreatic Neoplasms,Cancer

PROVIDER: 2230594 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR